Relief Therapeutics Holding AG (RLFTF)

[nelskof]

OK, Gee Gee you were close. This is my interpretation of the difference between the two synthetic VIP's based on JJ's comments and what I've been able to find so far.

There are two receptors that VIP targets and has 2 different functions.

PHAS version is the one that targets VPAC2. It's a modified peptide that is optimized for VPAC2. This is in the blood vessels and has a vaso dilating effect. This is the same type of VIP used for ED. The original intent is for pulmonary hypertension.

Aviptadil targets VPAC1 that is in the lung.

This difference could explain why you would get different results.

Thanks